Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2013 Apr 13;27(3):541–563. doi: 10.1016/j.hoc.2013.02.001

Table 4. Alternative Anticoagulants for Treatment of HIT.

Argatroban Bivalirudin Fondaparinux
Approval HIT or HIT patients undergoing
PCI with or at risk for HIT
Patients with or at risk of
developing HIT during PCI
Has not received FDA approval for use in HIT

Bolus None None N/A

Initial dose for
isolated HIT or
HIT with
thrombosis
1.5-2 mcg/kg/min100 0.15-0.2 mg/kg/h59 < 50 kg: 5 mg SC daily
50-100 kg: 7.5 mg SC daily
> 100 kg: 10 mg SC daily59

Initial dose for
renal
impairment
No adjustment necessary126 0.08-0.1 mg/kg/h (CrCl 30-60
mL/min)
Use with caution if CrCl 30-50 mL/min
0.03-0.05 mg/kg/h (CrCl < 30
mL/min or for patients receiving
renal replacement therapy)109
Contraindicated if CrCl < 30 mL/min116

Initial dose for
hepatic
impairment
0.5-1.2 mcg/kg/min100 No adjustment necessary127 No adjustment necessary116

Monitoring Obtain baseline aPTT and 2 hours
after starting infusion126
Obtain baseline aPTT and 2-3
hours after starting infusion
Anti-FXa activity can be monitored in renal
insufficiency115

Target aPTT 1.5-3 times the baseline
aPTT. Max goal aPTT=100 sec100
aPTT 1.5-2.5 times the baseline
aPTT59
N/A

Dosage
Adjustment
(HIT/HITTS
only)
Adjust infusion by 0.25-0.5
mg/kg/min to achieve goal aPTT.
Recheck aPTT 2-4 hours after each
dosage change.126
Adjust infusion by 20-25% to
achieve goal aPTT. Recheck aPTT
2 hours after each dosage change.
N/A

Maximum dose 10 mcg/kg/min 0.25 mg/kg/h127 10 mg daily116

Transition to
warfarin
Monitor chromogenic FXa level
while on combined therapy.101
Monitor INR and/or chromogenic
FXa while on combined therapy.
Monitor INR while on combined therapy.
Discontinue therapy when INR ≥ 2 for 2
consecutive days116
Chromogenic FXa:102
24-45% (INR 2-3)
15-35% (INR 2.5-3.5)
Chromogenic FXa:
24-45% (INR 2-3)
15-35% (INR 2.5-3.5)
Confirm INR 4-6 hours after
infusion is stopped

Cost of daily
therapy 107
$1313 $742 $103

Special
considerations
No antidote is available126 No antidote is available127 No antidote is available116
HIT in PCI:
0.75 mg/kg bolus followed by a
1.75 mg/kg/h infusion for the
duration of the procedure (all subgroups)
After PCI:
1.75 mg/kg/h (CrCl ≥ 30 mL/min)
1 mg/kg/h (CrCl < 30 mL/min)
0.25 mg/kg/h (hemodialysis)
Optional infusion after PCI 0.2
mg/kg/h for 20 hours127

Not applicable, N/A; creatinine clearance, CrCl; factor Xa, FX